Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Hamilton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2018 - 2021
Baylor College of MedicineClass of 2015
Certifications & Licensure
TX State Medical License 2024 - 2026
CA State Medical License 2019 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.Yi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton, Neha Agarwal, Hrishikesh K Srinagesh
Cancer Discovery. 2025-04-02 - Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.Mark P Hamilton, Ash A Alizadeh
Transplantation and Cellular Therapy. 2024-10-01 - 8 citationsCD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.Matthew J Frank, John H Baird, Anne Marijn Kramer, Hrishikesh K Srinagesh, Shabnum Patel
Lancet. 2024-07-27
Press Mentions
Development of T-cell Lymphoma 'Very Serious' but 'Very Rare' After CAR T-cell TherapyMarch 2nd, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
